Neratinib, pertuzumab o trastuzumab emtansina per al tractament adjuvant del càncer de mama precoç HER2+
Breast cancer (CM) is the most common cancer in women worldwide. In Spain, 32,953 new cases were diagnosed in 2019 and it is estimated that there are about 6,000-6,500 deaths a year from this cause. Breast cancer is a biologically diverse disease, with different subgroups defined according to their genomic or molecular characteristics. In the clinical field, three groups with different therapeutic needs are usually defined: tumors with positive estrogen (RE) +/– progesterone (RPg) hormone (RPg) hormone receptors (hormone-dependent or luminal) and negative HER2 (RH + and HER2–). ; HER2-positive tumors (overexpress HER2 protein), and triple-negative (TN) tumors (with RH and HER2-negative). Approximately 65-70% of cases are RH + and HER2 negative tumors; 15-20%, HER2 +, and 15%, TN .
Neratinib; Pertuzumab; Trastuzumab emtansine; HER2 + early breast cancer
Programa d'Harmonització Farmacoterapèutica. Neratinib, pertuzumab o trastuzumab emtansina per al tractament adjuvant del càncer de mama precoç HER2+. Barcelona: Servei Català de la Salut; 2020.
Use this identifier for quote and/or link this documenthttps://hdl.handle.net/11351/6291
This item appears in following collections
The following license files are associated with this item: